PCSK9 and ischemic stroke: In patients with a history of ischemic stroke who do not achieve LDL-C targets despite treatment with the maximal tolerated dose of a potent statin and ezetimibe, adding a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor should be considered according to current European and U.S. guidelines [10,11].